A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel, An Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Product Candidate, verses Investigator’s Choice of CD19 CAR T-Cell Therapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Second-Line Setting (PiNACLE-H2H)